Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.
Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office

ProAct
Resources

 

FDA Expands Indication on Entyvio®

FDA Expands Indication on Entyvio® hero image

In September 2023, the FDA approved the subcutaneous (SC) administration of Entyvio® for the maintenance treatment of adults with moderately to severely active ulcerative colitis (UC). On April 18, 2024, the FDA expanded the approval of Takeda’s Entyvio® (vedolizumab) to include…

FDA Approves Stelara Biosimilar, Selarsdi for Subcutaneous Use

FDA Approves Stelara Biosimilar, Selarsdi for Subcutaneous Use hero image

On April 16, 2024, the FDA approved Selarsdi (ustekinumab-aekn) for subcutaneous (SC) use as a biosimilar referencing Stelara (ustekinumab). Selarsdi is approved for only two of the indications that Stelara currently has approval for…

AstraZeneca and GSK Reduce Out-of-Pocket Cost For All Inhaled Drugs

AstraZeneca and GSK Reduce Out-of-Pocket Cost For All Inhaled Drugs hero image

Following the lead of drug manufacturer Bohringer Ingelheim (BI), both AstraZeneca and GSK have announced that they will restrict the out-of-pocket (OOP) cost for all their inhaled drugs to $35 or less per month. AstraZeneca’s program, which begins on June 1, 2024, includes…

FDA Approves First Interchangeable Biosimilar to High Concentration Humira

FDA Approves First Interchangeable Biosimilar to High Concentration Humira hero image

On February 23, 2024, the FDA approved Alvotech and Teva’s Simlandi (adalimumab-ryvk; formerly AVT02) injection, as an interchangeable biosimilar to high-concentration, citrate-free Humira. The high-concentration formulation accounts for…

2024 Evolution of ADA Guidelines

2024 Evolution of ADA Guidelines hero image

The American Diabetes Association (ADA) emphasizes the use of GLP-1 and GIP/GLP-1 receptor agonists in patients with type 2 diabetes who would benefit from weight and glycemic lowering benefits.  As the ADA guidelines have evolved, GLP-1 RA or GIP/GLP-1 RAs have been…

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image